Download linezolid suspension and tablet - Health Care Professionals Portal

OptumRx has partnered with CoverMyMeds to receive prior authorization requests,
saving you time and often delivering real-time determinations.
Visit go.covermymeds.com/OptumRx to begin using this free service.
Please note: All information below is required to process this request.
Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific
Zyvox® (linezolid) Prior Authorization Request Form (Page 1 of 2)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED
Member Information (required)
Provider Information (required)
Member Name:
Provider Name:
Insurance ID#:
NPI#:
Date of Birth:
Office Phone:
Street Address:
Office Fax:
City:
State:
Zip:
Phone:
Specialty:
Office Street Address:
City:
State:
Zip:
Medication Information (required)
Medication Name:
Strength:
 Check if requesting brand
 Check if request is for continuation of therapy
Directions for Use:
Dosage Form:
Clinical Information (required)
Select the diagnosis below:
 Chronic osteomyelitis or prosthetic joint infection caused by methicillin-resistant Staphylococcus aureus (MRSA) or
methicillin-resistant Staphylococcus epidermidis (MRSE)
 Community-acquired pneumonia caused by MRSA
 Community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus (MSSA)
 Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP])
 Complicated skin/skin structure infection (including diabetic foot infection) without osteomyelitis caused by MRSA
 Complicated skin/skin structure infection (including diabetic foot infection) without osteomyelitis caused by MSSA,
Streptococcus pyogenes, or Streptococcus agalactiae
 Empirical treatment of complicated skin/skin structure infection (including diabetic foot infection) without osteomyelitis
where MRSA infection is likely
 Empirical treatment of uncomplicated skin/skin structure infection where MRSA infection is likely
 Invasive vancomycin-resistant Enterococcus faecium (VRE) infection
 Nosocomial pneumonia caused by MRSA
 Nosocomial pneumonia caused by MSSA or Streptococcus pneumoniae (including MDRSP)
 Symptomatic lower urinary tract infection caused by VRE
 Uncomplicated skin/skin structure infection caused by MRSA
 Uncomplicated skin/skin structure infection caused by MSSA or Streptococcus pyogenes
 Other diagnosis: ______________________________ ICD-10 Code(s): _____________________________________
If the patient has End-Stage Renal Disease (ESRD), select all that apply:
 The medication is being used to treat infections related to ESRD
 The dialysis provider (i.e., nephrologist, nurse practitioner, physician assistant, or dialysis center) receives a monthly capitation payment
to manage the ESRD patient’s care
Continuation of therapy:
Is the requested medication being used for continuation of therapy upon hospital discharge?  Yes  No
Is the requested medication being used for continuation of therapy when transitioning from intravenous (IV) daptomycin (Cubicin), IV
vancomycin (Vancocin), IV tigecycline (Tygacil), IV telavancin (Vibativ), or IV linezolid (Zyvox) therapy?  Yes  No
If yes, please specify: ____________________.
Culture & Sensitivity:
Has the patient's diagnosis been confirmed by a culture and sensitivity report?  Yes  No
Diagnosis of chronic osteomyelitis or prosthetic joint infection:
Is this for reauthorization?  Yes  No
Will chart documentation be submitted to OptumRx® with this form, from an infectious disease specialist confirming that prolonged treatment
is necessary?  Yes  No
Infectious disease specialist:
Was the requested medication prescribed by or in consultation with an infectious disease specialist?  Yes  No
______________________________________________________________________________________________________________
This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider
named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose
PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information
in this document is against the law. If you are not the intended recipient, please notify the sender immediately.
Office use only: Zyvox_CMS_2017Jan1-W
Zyvox® (linezolid) Prior Authorization Request Form (Page 2 of 2)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED
Select the medications the patient has a failure, contraindication or intolerance to:
 Amoxicillin-clavulanate
 Carbapenems (e.g., Invanz, meropenem, imipenem-cilastin)
 Ampicillin-sulbactam
 Macrolides (e.g., azithromycin, clarithromycin, erythromycin)
 Cefotaxime
 Other cephalosporins (e.g., cefdinir, cefprozil, cephalexin)
 Ceftriaxone
 Other fluoroquinolones (e.g., ciprofloxacin)
 Clindamycin
 Other penicillins (e.g., amoxicillin, penicillin G)
 Dicloxacillin
 Other tetracyclines (e.g., minocycline, tetracycline)
 Doxycycline
 Levofloxacin
 Moxifloxacin (Avelox)
 Nitrofurantoin
 Trimethoprim-sulfamethoxazole (Bactrim)
Select the medications the patient has a resistance to:
 Amoxicillin-clavulanate
 Carbapenems (e.g., Invanz, meropenem, imipenem-cilastin)
 Ampicillin-sulbactam
 Macrolides (e.g., azithromycin, clarithromycin, erythromycin)
 Cefotaxime
 Other cephalosporins (e.g., cefdinir, cefprozil, cephalexin)
 Ceftriaxone
 Other fluoroquinolones (e.g., ciprofloxacin)
 Clindamycin
 Other penicillins (e.g., amoxicillin, penicillin G)
 Dicloxacillin
 Other tetracyclines (e.g., minocycline, tetracycline)
 Doxycycline
 Levofloxacin
 Moxifloxacin (Avelox)
 Nitrofurantoin
 Trimethoprim-sulfamethoxazole (Bactrim)
For brand Zyvox, select the medications the patient has a failure, contraindication, or intolerance to:
 Linezolid
 Zyvox suspension
Quantity limit requests:
What is the quantity requested per DAY? ______
What is the reason for exceeding the plan limitations?
 Titration or loading-dose purposes
 Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
 Requested strength/dose is not commercially available
 There is a medically necessary justification why the patient cannot use a higher commercially available strength to achieve the same
dosage and remain within the same dosing frequency. Please specify: _____________________________________________
 Other: ______________________________________________________________________________________________________
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to
this review?
________________________________________________________________________________________________________________
________________________________________________________________________________________________________________
Please note:
This request may be denied unless all required information is received.
If the patient is not able to meet the above standard prior authorization requirements, please call 1-800-711-4555.
For urgent or expedited requests please call 1-800-711-4555.
This form may be used for non-urgent requests and faxed to 1-800-527-0531.
______________________________________________________________________________________________________________
This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider
named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose
PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information
in this document is against the law. If you are not the intended recipient, please notify the sender immediately.
Office use only: Zyvox_CMS_2017Jan1-W